News
Prescient first in class cancer drug PTX-100 granted Orphan Drug status by the US FDA
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market exclusivity and other commercial benefits in blood cancer PTCL. Clinical…
News
Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
The designation brings considerable benefits including guaranteed market exclusivity for seven years and a waiver of Prescription Drug User Fee Act fees for orphan drugs,…
News
Prescient Therapeutics (ASX: PTX) Presentation – Switzer Small & Micro Cap Investor Day – July 2022
Prescient Therapeutics (ASX: PTX) Managing Director and CEO Steven Yatomi-Clarke presents at the Switzer Small & Micro Cap Investor Day July 2022 where he discusses…
News
Prescient Therapeutics granted key US patent for OmniCAR portfolio of therapies
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled ‘SpyCatcher and SpyTag: Universal Immune Receptor for T Cells’ that…
News
FIVE at FIVE AU: Iron ore cops a belting and energy prices could stay high until 2025
All the major banks have now lifted interest rates in line with the Reserve Bank of Australia’s cash rate hike of 0.5% yesterday, however that…
News
Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune receptor (UIR) platform.
News
Prescient (ASX: PTX) shares jump 6% on new US patent
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key US Patent for its OmniCAR portfolio “SpyCatcher and SpyTag: Universal…
News
Prescient Therapeutics delivers new clinic-ready cell therapy technology
Prescient Therapeutics Ltd (ASX:PTX)’s Steven Yatomi-Clarke outlines the company’s oncology treatment vision in a new interview with Proactive. The healthcare stock adopts a portfolio approach when…
News
Prescient (ASX: PTX) rolls out new cell therapy platform, CellPryme-M
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell therapy platform, “CellPryme-M”. It is a high-performance cell therapy manufacturing…
News
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy sector, unveiling its latest platform to advance CAR-T therapy globally….